Skip to content
Clinical Trials – home

ORL ambulance MUDr. Pavel Navratil

Research site

Czechia Borivojova 540/30a, 77900 Olomouc, Czechia

  • 1 trial recruiting
  • COVID-19 · Chronic rhinosinusitis with nasal polyps
  • Adults and children

About Specializations

ORL ambulance MUDr. Pavel Navratil in Olomouc, Czechia specialises in clinical trials of conditions such as COVID-19, Chronic rhinosinusitis with nasal polyps, and other specialisations. This site conducts important research.

Main research areas of the site

Otorhinolaryngology

The medical center is at the forefront of otorhinolaryngology, focusing on innovative treatments for conditions affecting the ear, nose, and throat. A key area of research is the management of Chronic Rhinosinusitis with Nasal Polyps, a condition that significantly impacts patients' quality of life.

  • Chronic Rhinosinusitis with Nasal Polyps
  • Advanced Endoscopic Techniques
  • Innovative Pharmacological Interventions

Through the study of Verekitug (UPB-101), the center is exploring new therapeutic avenues to enhance the efficacy and safety of treatments for nasal polyps, aiming to improve patient outcomes and reduce reliance on traditional nasal corticosteroids.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Borivojova 540/30a77900 OlomoucCzechia
Recruiting now
1 trial
Conditions studied
2

More sites in OlomoucCzechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

2 clinical trials

COVID-19

Recruiting

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Study on the Effects of Verekitug (UPB-101) for Patients with Chronic Rhinosinusitis with Nasal Polyps Using Nasal Corticosteroids

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.